Introduction {#s1}
============

The importance of patient-centeredness in the care of patients with type 2 diabetes is now widely accepted ([@B1]), and an understanding of patient preferences relevant to their diabetes treatment is a necessary part of achieving patient-centered care in diabetes. The issue of treatment preferences is especially complex in type 2 diabetes because of the range of medication alternatives; medication-related benefits, harms, and burden; and the likelihood, uncertainty, and time horizons of these treatment-related outcomes.

Patient preferences measure a patient's value for a specific outcome in relative (e.g., importance of weight loss vs. glycemic control) or absolute (e.g., importance of weight loss) terms ([@B2]). Additionally, patient preferences can be measured by how a patient chooses between treatment options or how a choice is influenced by the importance a patient places on a particular attribute of treatment. Preference measures differ from the better-studied patient-reported outcomes (PROs) such as health-related quality of life outcomes (HR-QoL) in that PROs provide information on a patient's status at one point in time (e.g., HR-QoL after treatment with metformin) ([@B2]). Patient preferences seek to evaluate the relative importance of the attributes that contribute to the patient status at a future point in time. In other words, HR-QoL and other PROs (e.g., gastrointestinal side effects vs. improved glycemic control with metformin) can be considered as attributes of medication for which patients can express a preference.

Even though patient preferences are deemed important by major diabetes professional societies ([@B1]), little is actually known about patient preferences for the treatment of type 2 diabetes ([@B2]). Therefore, we conducted a systematic review to identify and analyze studies of patient preferences in patients with type 2 diabetes not on insulin.

Research Design and Methods {#s2}
===========================

Study Design {#s3}
------------

We performed a systematic review of published studies that describe patient preferences for noninsulin diabetes medications (oral or injectable) in adults with type 2 diabetes. We also examined factors that could influence the risk of bias of study findings. A written study protocol was prepared in accordance with the PRISMA statement ([@B3]), and the review was registered with PROSPERO (systematic review record CRD42012002285).

Data Sources and Searches {#s4}
-------------------------

We searched the PubMed, Embase, CINAHL, and EconLit databases for studies published on or before 23 January 2013. Methodology and content experts within our team developed comprehensive search strategies to identify relevant studies. Our search terms consisted of key words for diabetes medication treatment, as well as methods used to assess patient preferences (e.g., conjoint analysis, decision analysis, utilities, and stated preferences) about medication treatment. The detailed search strategies are included within [Supplementary Table 1](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc13-2527/-/DC1).

Study Selection {#s5}
---------------

Two reviewers screened all titles independently. Titles were excluded if both reviewers determined that they did not meet inclusion criteria. Remaining articles and those with no titles proceeded to abstract review. Both reviewers independently screened abstracts of all remaining articles. Articles were excluded at this stage if both reviewers determined that they did not meet inclusion criteria. Disagreements about inclusion or exclusion based on abstract review were determined by consensus. Two investigators then reviewed the full text of all remaining articles and those with no abstracts. We included studies if they *1*) included adult patients with type 2 diabetes and *2*) assessed patient preferences related to medication treatment of type 2 diabetes. We defined a preference as a patient's a priori selection or rating of one treatment alternative over another, given a choice of at least two treatment options ([@B4]). We excluded articles if they *1*) were not written in English, *2*) did not assess patient treatment preferences, *3*) included only patients \<18 years old, *4*) contained no original data (e.g., review, commentary, editorial, or meeting abstract), *5*) only assessed preferences for treating diabetes complications or comorbid medical conditions, *6*) only included nonmedication diabetes treatment, *7*) only assessed patient satisfaction with or adherence to treatment, or *8*) only included insulin therapy. Consensus on study inclusion was reached by at least two reviewers.

Data Extraction and Quality Assessment {#s6}
--------------------------------------

For each article that met our inclusion criteria, two reviewers extracted data, including information on study design, treatments compared, locations, sample size, participant characteristics, preference elicitation methods, funding sources, and treatment-related attributes associated with patient preferences. Reviewers resolved disagreements by discussion and adjudication with a third party (i.e., a health economist with expertise in assessing patient treatment preferences).

Two reviewers used a checklist adapted from previously published instruments evaluating general study quality ([@B5],[@B6]) and the Purpose, Respondents, Explanation, Findings, Significance (PREFS) checklist ([@B4]) specifically developed based on guidelines for conjoint analysis, PROs, and randomized and nonrandomized trials to independently assess study reporting on factors that could influence the validity of findings, including study external validity (i.e., well-described inclusion and exclusion criteria) and factors influencing study internal validity (i.e., a well-defined study question that includes key PICOTS \[population, intervention, comparator, outcomes, timing, and settings\] components \[[@B6]\], a comprehensive description of treatment alternatives, appropriate measurement of patient preferences, appropriate analytical techniques for the given data, and prespecified analysis \[[Supplementary Table 2](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc13-2527/-/DC1)\]).

Data Synthesis and Analysis {#s7}
---------------------------

We decided a priori not to statistically combine results in a meta-analysis because we expected studies to be methodologically and clinically diverse. For instance, some studies ranked patient preferences using conjoint analysis or an alternative discrete choice experiment whereas others reported patient utilities for a particular treatment. Therefore, we qualitatively synthesized results for individual studies within summary evidence tables to help clarify the similarities and differences among studies that appear to address similar research questions across a variety of measures and patient populations.

Results {#s8}
=======

Search Results {#s9}
--------------

Of 2,811 total citations (613 in PubMed, 1,437 in Embase, 739 in CINAHL, and 22 in EconLit), 211 articles were eligible for full text review. We included 10 studies that met our inclusion criteria in the final review ([@B7]--[@B16]) ([Fig. 1](#F1){ref-type="fig"}).

![Summary of literature search and article review process.](2055fig1){#F1}

Study Characteristics {#s10}
---------------------

Eligible studies were conducted from 2007 to 2012. All studies were cross-sectional, and sample sizes ranged from 129 to 1,355 participants. Half of the studies were performed in the U.S. ([@B9]--[@B11],[@B15],[@B16]), and the remaining studies included participants from Sweden ([@B12],[@B13]), Denmark ([@B7]), and the U.K. ([@B8],[@B11],[@B14]). Industry/pharmaceutical companies funded the majority of the studies ([@B7],[@B8],[@B11]--[@B16]) ([Table 1](#T1){ref-type="table"}).

###### 

Study characteristics

  Year                                                                         Author     Location            Design            Sample size   Patient population (age, sex, diabetes duration)   Method                                    Funding
  ---------------------------------------------------------------------------- ---------- ------------------- ----------------- ------------- -------------------------------------------------- ----------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------
  2012                                                                         Jendle     Sweden              Cross-sectional   461           Age: N/R                                           Willingness to pay                        Novo Nordisk A/S, Scandinavia
  Male: N/R                                                                                                                                                                                                                                
  Duration: N/R                                                                                                                                                                                                                            
  2011                                                                         Bøgelund   Denmark             Cross-sectional   270           Age: 81% ≥50 years                                 Willingness to pay                        Novo Nordisk A/S, Denmark
  Sex: 66% male                                                                                                                                                                                                                            
  Duration: 62% \>5 years                                                                                                                                                                                                                  
  2011                                                                         Boye       Scotland            Cross-sectional   151           Age (mean): 59.2 years                             Standard gamble and visual analog scale   Eli Lilly and Company
  Sex: 66.2% male                                                                                                                                                                                                                          
  Mean age at diagnosis: 51.9 years                                                                                                                                                                                                        
  2011                                                                         Polonsky   U.S.                Cross-sectional   1,355         Age (mean): 58.02 years                            Survey with Likert ratings scale          Amylin Pharmaceuticals; Eli Lilly and Company
  Sex: 54.8% male                                                                                                                                                                                                                          
  Mean duration: 10.09 years                                                                                                                                                                                                               
  2010                                                                         Jendle     Sweden              Cross-sectional   461           Age: 96.4% ≥50 years                               Willingness to pay                        Novo Nordisk, ESP Bioscience
  Sex: 63.1% male                                                                                                                                                                                                                          
  Duration: 62% \>5 years                                                                                                                                                                                                                  
  2010                                                                         Polster    U.S.                Cross-sectional   382           Age (mean): 52.7 years                             Conjoint exercise and time tradeoff       Novo Nordisk A/S, Denmark
  Sex: 48% male                                                                                                                                                                                                                            
  Mean duration: 7.6 years                                                                                                                                                                                                                 
  2009                                                                         Hauber     U.S.; U.K.          Cross-sectional   407           Age (mean): 57 years                               Discrete choice experiment                Novartis Pharmaceuticals
  Sex: 62% male                                                                                                                                                                                                                            
  Duration: 81% = 1--10 years                                                                                                                                                                                                              
  2008                                                                         Brown      U.S.                Cross-sectional   332           Age: 100% ≥65 years                                Time tradeoff                             National Institutes of Health; Centers for Disease Control and Prevention; Chicago Center of Excellence in Health Promotion Economics
  Sex: 42% male                                                                                                                                                                                                                            
  Mean duration: 13 years (vulnerable group); 10 years (nonvulnerable group)                                                                                                                                                               
  2008                                                                         Chin       U.S.                Cross-sectional   473           Age (mean): 73.7 years                             Time tradeoff and visual analog scale     National Institutes of Health; Robert Wood Johnson Foundation
  Sex: 37% male                                                                                                                                                                                                                            
  Mean duration: 13.2 years                                                                                                                                                                                                                
  2007                                                                         Matza      Scotland; England   Cross-sectional   129           Age (mean): 55.9 years                             Standard gamble                           Eli Lilly and Company
  Sex: 64.3% male                                                                                                                                                                                                                          
  Mean age at diagnosis: 49.3 years                                                                                                                                                                                                        

Methodological Quality of Included Studies {#s11}
------------------------------------------

All studies included a well-defined study question and conducted prespecified analyses. The majority described their inclusion and exclusion criteria well (70%), provided a comprehensive description of treatment alternatives (90%), used appropriate measures to assess patient preferences (90%), and conducted analyses that were appropriate for the study data (80%) ([Supplementary Table 3](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc13-2527/-/DC1)).

Methods Used to Assess Patient Preferences {#s12}
------------------------------------------

Methods to assess patient preferences for noninsulin diabetes medications included the following: discrete choice experiments ([@B7],[@B11]--[@B13]), time tradeoff methods ([@B9],[@B10]), conjoint analysis exercises combined with time tradeoff ([@B16]), survey questions with Likert-type ratings scales ([@B15]), and standard gamble ([@B8],[@B14]) ([Tables 1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}).

###### 

Attributes examined when assessing patient preferences for noninsulin diabetes medications

                                                                                                                                                                                                                                                      Attributes examined when assessing patient preferences                              
  ------------------------------ ----------------------- -------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------- -------------------------------------------------------- -------------------------- ----------------------------
  2012                           Jendle                  Current medication vs. hypothetical drug (i.e., liraglutide, rosiglitazone, exenatide)                         Willingness to pay                                                            Weight loss/control                                      Administration frequency   Gastrointestinal effects
  Glycemic control (HbA~1c~)     Blood glucose testing   Hypoglycemia events                                                                                                                                                                                                                                                              
  Systolic blood pressure                                                                                                                                                                                                                                                                                                                 
  2011                           Bøgelund                Oral antidiabetes drugs vs. injections                                                                         Willingness to pay (Danish kroner per month)                                  Glycemic control (HbA~1c~)                               Mode of administration     Hypoglycemia events
  Weight loss/control            Blood glucose testing   Transient nausea                                                                                                                                                                                                                                                                 
  Blood pressure control         Payment per month                                                                                                                                                                                                                                                                                        
  Improved heart function                                                                                                                                                                                                                                                                                                                 
  Possess driver's license                                                                                                                                                                                                                                                                                                                
  2011                           Boye                    Hypothetical scenarios (i.e., oral medicine only vs. oral medicine plus daily injections)                      Visual analog scale exercise and standard gamble vignette-based assessments                                                            Dose frequency             Injection site reactions
  Dose flexibility (mealtimes)                                                                                                                                                                                                                                                                                                            
  2011                           Polonsky                Oral medication vs. injectable medication                                                                      Patient-reported willingness to take medication given potential factors       Glycemic control                                         Treatment frequency        Hypoglycemia events
  Weight loss/control            Costs                                                                                                                                                                                                                                                                                                    
  2010                           Jendle                  Oral antidiabetes drugs vs. injections                                                                         Willingness to pay (Swedish krona/euro per month)                             Glycemic control (HbA~1c~)                               Mode of administration     Hypoglycemia events
  Weight loss/control            Blood glucose testing   Transient nausea                                                                                                                                                                                                                                                                 
  Blood pressure control         Payment per month                                                                                                                                                                                                                                                                                        
  Improved heart function                                                                                                                                                                                                                                                                                                                 
  2010                           Polster                 Liraglutide vs. exenatide                                                                                      Conjoint exercise and time tradeoff                                           Glycemic control (HbA~1c~)                               Dosing schedule            Nausea
  Hypoglycemia                                                                                                                                                                                                                                                                                                                            
  2009                           Hauber                  Hypothetical oral medication profiles                                                                          Discrete choice experiment                                                    Glycemic control (HbA~1c~)                                                          Hypoglycemia events
  Water retention                                                                                                                                                                                                                                                                                                                         
  Weight gain                                                                                                                                                                                                                                                                                                                             
  Mild stomach upset                                                                                                                                                                                                                                                                                                                      
  Heart attack risk                                                                                                                                                                                                                                                                                                                       
  2008                           Brown                   Intensive vs. conventional glucose control; comprehensive diabetes care vs. comprehensive care with polypill   Time tradeoff questions                                                                                                                Method of delivery         Likelihood of side effects
  Laboratory testing                                                                                                                                                                                                                                                                                                                      
  2008                           Chin                    Intensive therapy vs. conventional treatment                                                                   Time tradeoff and visual analog scale                                         Avoid complications                                      Treatment intensity        
  Life expectancy                                                                                                                                                                                                                                                                                                                         
  2007                           Matza                   Hypothetical type 2 diabetes--related health states                                                            Standard gamble                                                               Weight loss/control                                                                 Weight gain
  Nausea                                                                                                                                                                                                                                                                                                                                  
  Hypoglycemia                                                                                                                                                                                                                                                                                                                            

Types of Treatment Comparisons Included When Assessing Patient Preferences {#s13}
--------------------------------------------------------------------------

Studies compared a variety of noninsulin diabetes medications when assessing patient preferences for treatment. These comparisons included specific diabetes medications, such as liraglutide, rosiglitazone, and exenatide ([@B12],[@B16]), as well as broader categories of medication types (e.g., oral drugs vs. injections) ([@B7],[@B13],[@B15]). Several studies included hypothetical medication profiles of treatment attributes (e.g., intensive vs. conventional treatment) to assess patient preferences ([@B8]--[@B12],[@B14]) ([Table 2](#T2){ref-type="table"}).

Attributes Associated With Patient Treatment Preferences {#s14}
--------------------------------------------------------

### Treatment Benefits {#s15}

Attributes related to treatment benefits included treatment efficacy in improving glycemic control, patient weight loss or control, blood pressure control, and heart function, as well as factors associated with enhanced quality of life, such as higher life expectancy, the avoidance of diabetes complications, and the ability to possess a driver's license. Of these, glycemic control was the most frequently examined benefit ([@B7],[@B11],[@B13],[@B15],[@B16]), followed by weight loss/control ([@B7],[@B12],[@B13],[@B15]).

### Treatment Burden {#s16}

Attributes related to treatment burden examined within studies included the method of delivery and mode of administration, dose frequency and flexibility, required blood glucose and laboratory testing, treatment-related costs, and treatment intensity. Of these, treatment/dose frequency and method of delivery/mode of administration were the most frequently examined ([@B7],[@B12],[@B13],[@B15],[@B16]).

### Side Effects {#s17}

Potential treatment-related side effects examined within studies included gastrointestinal effects (e.g., transient nausea and upset stomach), hypoglycemia, injection site reactions, weight gain, water retention, and increased risk of heart attacks. Hypoglycemia was the most frequently examined side effect ([@B7],[@B11]--[@B13],[@B15],[@B16]), followed by gastrointestinal effects ([@B7],[@B11]--[@B13],[@B16]) ([Table 2](#T2){ref-type="table"}).

Relative Importance of Treatment Benefits Versus Treatment Burden and Side Effects When Assessing Patient Treatment Preferences {#s18}
-------------------------------------------------------------------------------------------------------------------------------

Seven of the included studies provided results (total of 54 direct comparisons) on the relative importance of treatment benefits and treatment burden and side effects in their assessment of patient preferences for noninsulin diabetes medications ([@B7],[@B8],[@B11]--[@B13],[@B15],[@B16]). The most common attribute comparisons were weight loss/control and glycemic control versus treatment-related burden and side effects ([Table 3](#T3){ref-type="table"}).

###### 

Relative importance of treatment benefits versus treatment burden and side effects when assessing patient preferences for noninsulin diabetes medications

                                     Treatment benefits                                                                                                                                                                                                                                          
  ---------------------------------- -------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------ --------------------------------------- --------------------------------------- -----------------------
  Treatment burden                   Attribute ranked as most important (number of times ranked most important/total number of study comparisons)                                                                                                                                                
   Administration or frequency       Weight loss/control (4/4) ([@B7],[@B12],[@B13],[@B15])                                                         Glycemic control (4/4) ([@B7],[@B13],[@B15],[@B16])          Administration (1/1) ([@B13])           Heart function (2/2) ([@B7],[@B13])     License (1/1) ([@B7])
   Cost/payment                      Weight loss/control (1/1) ([@B15])                                                                             Glycemic control (1/1) ([@B15])                              ---                                     ---                                     ---
   Glucose testing                   Weight loss/control (2/2) ([@B12],[@B13])                                                                      Glycemic control (1/1) ([@B13])                              Blood pressure control (1/1) ([@B13])   Heart function (1/1) ([@B13])           ---
  Side effects                       Attribute ranked as most important (number of times ranked most important/total number of study comparisons)                                                                                                                                                
   Gastrointestinal effects/nausea   Weight loss/control (3/3) ([@B7],[@B12],[@B13])                                                                Glycemic control (2/4) ([@B11],[@B16])                       Gastrointestinal (1/1) ([@B13])         Gastrointestinal (2/2) ([@B7],[@B13])   License (1/1) ([@B7])
   Hypoglycemia                      Weight loss/control (4/4) ([@B7],[@B12],[@B13],[@B15])                                                         Glycemic control (5/5) ([@B7],[@B11],[@B13],[@B15],[@B16])   Blood pressure control (1/1) ([@B13])   Heart function (2/2) ([@B7],[@B13])     License (1/1) ([@B7])
   Weight gain                       Weight loss/control (2/3) ([@B7],[@B15])                                                                       Glycemic control (2/4) ([@B7],[@B11])                        Weight gain (1/1) ([@B13])              Heart function (1/2) ([@B7])            License (1/1) ([@B7])

In four studies (17 total comparisons), patients ranked weight loss/control as more important than treatment administration or frequency (4 of 4 comparisons), cost (1 of 1 comparison), glucose testing (2 of 2 comparisons), gastrointestinal effects (3 of 3 comparisons), hypoglycemia (4 of 4 comparisons), and potential weight gain (2 of 3 comparisons) ([@B7],[@B12],[@B13],[@B15]). Similarly, in five studies (19 total comparisons) ([@B7],[@B11],[@B13],[@B15],[@B16]), glycemic control was ranked more important than treatment administration (4 of 4 comparisons), cost (1 of 1 comparison), glucose testing (1 of 1 comparison), gastrointestinal effects (2 of 4 comparisons), risk of hypoglycemia (5 of 5 comparisons), and potential weight gain (2 of 4 comparisons). Improved heart function was ranked as more important than treatment administration (2 of 2 comparisons), glucose testing (1 of 1 comparison), risk of hypoglycemia (2 of 2 comparisons), and potential weight gain (1 of 2 comparisons) in two studies ([@B7],[@B13]). However, risk of gastrointestinal effects was ranked as more important than improved heart function (2 of 2 comparisons) in these two studies ([@B7],[@B13]). Additional results on comparisons evaluated in a single study ([@B7]) are provided in [Table 3](#T3){ref-type="table"}.

Conclusions {#s19}
===========

In this systematic review, we identified weight loss/control and glycemic control as key attributes of diabetes treatment that drive patient preferences when these factors were compared with treatment burden and side effects. Gastrointestinal effects were ranked as more important than hypoglycemia by patients within the included studies. Evidence on patient preferences related to other treatment-related attributes of risk and burden was sparse.

For the clinician, our review provides the best available information on the relative importance to patients of factors that likely influence their treatment decision making related to noninsulin medications for type 2 diabetes. Type 2 diabetes is a particularly preference-sensitive condition because of the multitude of available treatments, which have varied benefits, risks, and burdens. In this study, we identified weight loss/control, glycemic control, and gastrointestinal side effects as particularly important to patients when considering treatment side effects/burden. Of note, patient BMI was also reported to be significantly associated with patient preferences about weight loss/control (e.g., patients with a BMI \>30 kg/m^2^ reported a higher willingness to pay for weight reduction than patients with a BMI \<30 kg/m^2^) ([@B7],[@B13]). Although these findings may not apply to individual patients, the consistency of results should raise awareness of the importance of these factors in the initiation and evaluation of medication outcomes. For example, perceived ineffectiveness of a medication on the part of a clinician could actually be related to nonadherence because of side effects that could be avoided with a different medication; a priori understanding of patient preferences could prevent these types of treatment obstacles. An important consideration in interpreting our results is that they apply to noninsulin diabetes medications generally; in fact, most studies did not focus on a specific medication, and only one study compared patient preferences relative to two specific medications (liraglutide and exenatide) ([@B16]); the others either did not specify medications (e.g., oral hypoglycemic vs. injectables) ([@B7],[@B13],[@B15]) or used hypothetical scenarios ([@B8]--[@B12],[@B14]). Clinically, we expect that preferences for treatment-related attributes are independent of the specific treatment (e.g., a patient's preference for gastrointestinal side effects relative to hypoglycemia should be the same regardless of which medication is causing these side effects), and therefore, understanding general preferences regarding benefits and risks can be considered with specific medication attribute profiles to facilitate the overall medication decision. Thus, the included studies of both real and hypothetical medication profiles provide relevant information on preferences for treatment and move us closer to patient-centered care in diabetes.

A major strength of this review is the conduct of a carefully designed literature search of several databases and the use of detailed methods consistent with PRISMA guidelines ([@B3]) throughout the study. We also used a detailed quality assessment instrument to evaluate factors influencing the risk of bias of study findings and anticipate that this instrument could be used in the future evaluation of preference studies. Included studies were conducted among both men and women with variation in age; were diverse in setting; and used a variety of methods to assess preferences, including discrete choice experiments, time tradeoff methods, standard gamble, and survey questionnaires. A majority of studies included a well-defined study question, described their inclusion and exclusion criteria well, and provided a comprehensive description of treatment alternatives.

As with all systematic reviews, the strength of our conclusions is dependent on the quality of available studies, and limitations of our study deserve consideration. We found that all of the studies meeting our inclusion criteria reported outcomes at a single time point, with many studies incorporating hypothetical scenarios or medication profiles. Thus, we were unable to assess the extent to which reported patient preferences align with actual treatment decision making when patients are faced with these decisions in real-world settings, and we could not evaluate patient preferences regarding treatment benefits or side effects over time. Also, studies rarely performed subgroup analyses of patient preferences and did not always account for important clinical (e.g., comorbidities) and demographic characteristics (e.g., race/ethnicity) that could potentially influence patient treatment preferences. Although all of the studies that performed statistical analyses conducted analyses that were appropriate for study data, there were several studies that performed little or no statistical analyses. Our quality assessment tool did not explicitly penalize studies for not performing statistical analyses, and thus this important limitation of assessing study internal validity should be noted. Although this literature provided evidence on patient preferences using a wide variety of methods, differences between preference assessment methods may have influenced the relative values patients placed on treatment-related attributes. Few studies tested whether using multiple preference assessment methods, such as both conjoint analysis and time tradeoff methods, would result in different patient choices. Studies also varied in their presentation of preference choices to patients. For example, some studies described "gastrointestinal effects" as transient nausea whereas other studies described it as upset stomach. Thus, caution is required when comparing the relative importance of treatment-related attributes across studies. We did exclude non--English language articles, but the included studies were comprised of differing patient populations representing five countries. Therefore, we anticipate that the exclusion of any non--English language articles would not significantly change our observed findings. Finally, the majority of studies were funded by pharmaceutical and device manufacturing companies, which may introduce the risk of publication bias.

To date, the evidence base for high-quality comparative effectiveness research on how attributes of treatment efficacy, treatment burden, and potential side effects drive patient preferences for management of type 2 diabetes has been relatively lean. To our knowledge, we provide the first systematic review of patient preferences for noninsulin diabetes medication among adults with type 2 diabetes. Our review provides a comprehensive synthesis of available evidence regarding attributes of diabetes medication that are important to patient-centered decision making in the noninsulin treatment of type 2 diabetes.

One important consideration addressed by our methodology should be explored in future studies. Since there is a lack of a widely accepted definition of patient preferences and how they should be measured, we adopted a working theoretical definition of preferences, which most closely resembles the economics conceptualization of preferences, to guide our study inclusion criteria ([@B4]). On this basis, it is possible that we excluded articles that may contain useful preference information because they used definitions that did not meet our inclusion criteria. However, the uniform application of selection criteria is the bedrock of a well-conducted systematic review, and we believe that our definition of preferences was sensitive and specific, enabling us to identify the relevant articles. Guidelines on the definition of preferences are needed, and we believe that our study can provide a starting point for these.

Finally, preferences for treatment-related attributes must be combined with the probability of treatment-related outcomes to make a patient-centered decision. These types of analyses are outside the scope of the current study, but future studies should apply proven decision analysis methods, such as the Analytic Hierarchy Process ([@B17]). We describe the use of this method for medication decision making in type 2 diabetes in a separate article ([@B18]).

In summary, our systematic review of the evidence on patient preferences relevant to noninsulin type 2 diabetes medications reveals that weight loss/control and glycemic control may drive patient preferences when compared with treatment-related burden and side effects. Of the studied medication side effects, risk of gastrointestinal effects was an important attribute associated with treatment preferences. Clinicians can consider the patient preferences identified in this study in the care of their patients, and researchers should build upon this by developing evidence-based guidelines for the future conduct and evaluation of preference studies. Preference elicitation provides a necessary stepping stone in the path to individualized care and patient-centered decision making in type 2 diabetes as recommended by major professional organizations ([@B1],[@B19]). Ultimately, we must develop and implement clinical decision support tools that incorporate preferences in order to truly provide patient-centered care in the treatment of type 2 diabetes.

This article contains Supplementary Data online at <http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc13-2527/-/DC1>.

**Acknowledgments.** The authors sincerely thank Sonal Singh, Johns Hopkins University School of Medicine, Baltimore, MD, and Jodi Segal, Johns Hopkins University School of Medicine, Baltimore, MD, for their contributions to the conception and planning of this study.

**Funding.** This study was supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health (Grant 5T32-HL-007180 to T.S.P.) and from the U.S. Food and Drug Administration, Department of Health and Human Services (Contract HHSF2232010000072C to S.J., E.L., J.F.P.B., and N.M.).

The funders had no role in the design and conduct of the study, interpretation of the data, or preparation of the manuscript.

**Duality of Interest.** No potential conflicts of interest relevant to this article were reported.

**Author Contributions.** T.S.P. developed the criteria for identifying preference studies and rating their quality, conducted the systematic review, and led the writing of the manuscript. S.J. and E.L. developed the criteria for identifying preference studies and rating their quality and conducted the systematic review. J.F.P.B. developed the criteria for identifying preference studies and rating their quality. N.M. developed the criteria for identifying preference studies and rating their quality, conducted the systematic review, provided clinical insights, and led the writing of the manuscript. All authors contributed to the writing of the manuscript and approved the final version.
